checkAd
    Startseite > Aktien > Veru > Nachrichten
    Veru Aktie
    1,3460
     
    EUR
    -0,59 %
    -0,0080 EUR
    Letzter Kurs 15.05.24 Tradegate
    1,3350
     
    EUR
    2.252 STK
    Geldkurs 13:27:50
    1,3740
     
    EUR
    2.185 STK
    Briefkurs 13:27:50
    ISIN: US92536C1036 · WKN: A2DV3C · SYM: FMW · USA

    Neueste Nachrichten

    Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
    15.05.24 · globenewswire · Veru
    Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
    14.05.24 · globenewswire · Veru
    Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
    08.05.24 · globenewswire · Veru
    Veru to Present at the GLP-1 Based Therapeutics Summit
    02.05.24 · globenewswire · Veru
    Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024
    01.05.24 · globenewswire · Veru
    Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
    30.04.24 · globenewswire · Veru
    Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
    25.04.24 · globenewswire · Veru
    Veru Announces Date of 2024 Annual Meeting of Shareholders
    01.04.24 · globenewswire · Veru
    Veru Reschedules Annual Meeting of Shareholders
    22.03.24 · globenewswire · Veru
    Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
    12.03.24 · globenewswire · Veru
    Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
    28.02.24 · globenewswire · Veru
    Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
    20.02.24 · globenewswire · Veru